Ohio State University Trials Atropine for Delaying Nearsightedness in Children
The DONUT trial will evaluate the efficacy of 0.05% atropine drops in delaying nearsightedness in children compared to placebo.
Phase III
Ophthalmology / Myopia
Status
Active
Signal Score
8.2
Signal assessment
Signal strength
high
Confidence level
moderate
Why it matters
The DONUT trial is critical as it explores the potential of atropine to delay myopia onset in children, which could redefine treatment standards in pediatric ophthalmology. A successful outcome may shift competitive dynamics and influence future product development strategies in this therapeutic area.
Recommended action
Humanexa recommends Monitor.
Analysis
Monitor the trial's primary outcome results and any subsequent publications on atropine's long-term effects on eye growth.
Related companies & assets
Assets
Sources & Humanexa intelligence
Related signals
Newsletter
Get signals before the market moves
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.